MJFF Therapeutics Pipeline Program — Pre-Proposals
Supports Parkinson's disease research teams in the MJFF Therapeutics Pipeline with sustained coaching toward therapeutic candidate development.
Eligibility · Global — open worldwide
The Michael J. Fox Foundation for Parkinson's Research Therapeutics Pipeline Program is one of the largest private grant mechanisms dedicated to advancing disease-modifying and symptomatic interventions for Parkinson's disease. Founded in 2000, MJFF has raised more than $2 billion for Parkinson's research and in 2022 funded more PD research than the U.S. government. The Therapeutics Pipeline Program funds pre-clinical development over one to two years and clinical-stage projects over two to three years, with individual awards ranging from $250,000 to over $5 million depending on stage and scope. A defining feature is that industry organizations are the preferred applicant — a rare policy among research funders — making for-profit biotechnology and pharmaceutical companies directly eligible alongside academic-industry partnerships and academic-led projects qualifying via RFA exemptions.
The 2025–2027 cycle accepts pre-proposals on a rolling basis, with five annual full-proposal cycles spanning October 9, 2025 through January 8, 2027; award announcements are made within three months of each cycle close. The program funds the development of disease-modifying or symptomatic interventions and integration of decision-informing biomarker tools. Explicitly excluded are early-stage target discovery, tool compound validation, standalone biomarker discovery, simple therapy reformulation, dietary supplements, and natural history studies. There are no geographic restrictions — international teams are eligible.
Applicants should download the RFA overview plus the appropriate pre-clinical or clinical template from grants.michaeljfox.org before beginning. MJFF's Open Science Policy requires sharing of data, preprints, code, and software with persistent identifiers. Teams should confirm the current cycle deadline on the grants portal, as the rolling pre-proposal window feeds five distinct full-proposal cycles. Indirect cost policies are not specified in the RFA overview and should be confirmed with MJFF directly.
Pre-clinical and clinical development of disease-modifying or symptomatic interventions for Parkinson's disease, including integration of decision-informing biomarker tools.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Sign up free to see where teams trip up